Reuters logo
BRIEF-Allergan enters parkinson's disease through option arrangement with Lysosomal Therapeutics
January 9, 2017 / 2:30 PM / a year ago

BRIEF-Allergan enters parkinson's disease through option arrangement with Lysosomal Therapeutics

Jan 9 (Reuters) - Allergan Plc :

* Allergan enters parkinson’s disease through option arrangement with Lysosomal Therapeutics Inc (LTI) for its potential first-in-class breakthrough compounds

* Allergan Plc - additional terms were not disclosed.

* Allergan Plc - purchased an option right directly from LTI shareholders to acquire LTI following completion of a phase 1b trial for LTI-291

* Allergan Plc - option to acquire LTI following completion of phase 1B clinical trial

* Allergan Plc - Allergan will provide a separate upfront research and development payment

* Allergan Plc - Allergan and LTI will establish a joint development committee to oversee development activities for LTI-291 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below